Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Clinical Diabetes
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1451383
This article is part of the Research Topic Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - Pathogenesis, Prevention and Treatment View all 3 articles

Associating Plasma Aldosterone Concentration with the Prevalence of MAFLD in Hypertensive Patients: Insights from a Large-Scale Cross-Sectional Study

Provisionally accepted
Di Shen Di Shen Xintian Cai Xintian Cai Junli Hu Junli Hu *Shuaiwei Song Shuaiwei Song *Qing Zhu Qing Zhu *Huimin Ma Huimin Ma *Yingying Zhang Yingying Zhang *Rui Ma Rui Ma *Pan Zhou Pan Zhou *Wenbo Yang Wenbo Yang *Jing Hong Jing Hong *Delian Zhang Delian Zhang *Nanfang Li Nanfang Li *
  • People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China

The final, formatted version of the article will be published soon.

    Objective: To explore the link between plasma aldosterone concentration (PAC) and the prevalence of metabolic dysfunction-related fatty liver disease (MAFLD) in hypertensive patients.We analyzed data from 41,131 hospitalized patients from January 1, 2014, to December 31, 2023. Multivariate logistic regression models tested associations, with threshold, subgroup, and sensitivity analyses conducted to validate findings.For each 5-unit increase in PAC, the risk of MAFLD rose by 1.57 times, consistent even in the fully adjusted model. The odds ratios for the Q2, Q3, and Q4 groups compared to Q1 were 1.21, 2.12, and 3.14, respectively. A threshold effect was observed at 14 ng/dL, with subgroup and sensitivity analyses supporting these results.This study reveals a significant positive association between elevated PAC levels and the prevalence of MAFLD in hypertensive patients. These findings underscore the imperative for further large-scale, prospective studies to validate and expand upon this correlation.

    Keywords: Plasma aldosterone concentration, metabolicdysfunctionassociated fatty liver disease, Hypertension, Cross-sectional study, risk factors 1. Introduction

    Received: 19 Jun 2024; Accepted: 30 Aug 2024.

    Copyright: © 2024 Shen, Cai, Hu, Song, Zhu, Ma, Zhang, Ma, Zhou, Yang, Hong, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Junli Hu, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Shuaiwei Song, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Qing Zhu, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Huimin Ma, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Yingying Zhang, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Rui Ma, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Pan Zhou, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Wenbo Yang, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Jing Hong, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Delian Zhang, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China
    Nanfang Li, People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.